81
Participants
Start Date
July 31, 2004
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
Citalopram
Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
Placebo
Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
The Research Institute at Nationwide Children's Hospital, Columbus
National Institute of Mental Health (NIMH)
NIH
John V. Campo, M.D.
OTHER